Clinical trials: Safety After Oral Intake
Healthy
Safety and Tolerability of CFTX-1554 in Healthy Subjects
The study will consist of 2 parts, i.e. a single ascending dose part with integrated food effect assessment and assessment of relative bioavailability (Part A), and a multiple ascending dose part (Part B).
- Trial name
- NCT05260658
- Testing
- CFTX-1554
- Where
- Netherlands
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Confo Therapeutics
Pharmacokinetics After Oral Intake
Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents
The goal of this clinical trial is to evaluate the use of sulopenem etzadroxil plus probenecid in adolescent patients being treated for bacterial infection.
- Trial name
- NCT07092813
- Testing
- sulopenem etzadroxil and probenecid
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Iterum Therapeutics, International Limited
Healthy
Oral Bioavailability of GLPG0555 in Different Solid Formulations
The purpose of the study is to compare the pharmacokinetics of a solid capsule formulation of GLPG0555 with a nanosuspension, and to assess safety and tolerability of a single dose of GLPG0555.
- Trial name
- NCT01278095
- Testing
- GLPG0555 solid dispersion, GLPG0555 nanosuspension
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Healthy
Oral Bioavailability of Two Solid Formulations of GLPG0259.
The purpose of the study is to evaluate the relative bioavailability of two solid oral formulations of GLPG0259 administered after a meal.
- Trial name
- NCT01322451
- Testing
- GLPG0259 fumarate, GLPG0259 free base
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Healthy
GLPG0259 Solid Formulation Bioavailability and Food Effect
The purpose of the study is to compare the pharmacokinetics of GLPG0259 as a solid dosage formulation (with and without food)and an oral solution, and to assess its safety and tolerability.
- Trial name
- NCT01024517
- Testing
- GLPG0259 solution, GLPG0259
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Safety After Oral Intake
Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants
The goal of this clinical trial is to learn if drug MDI2517 is safe and to learn more about its drug effects in healthy participants.
- Trial name
- NCT07220889
- Testing
- MDI-2517 800mg, MDI-2517 1600mg, MDI-2517 2400mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MDI Therapeutics, Inc.